|
humans |
37 |
|
animals |
27 |
|
male |
26 |
|
propofol |
25 |
|
analgesia |
23 |
|
diabetes |
23 |
|
female |
22 |
|
oxidative stress |
21 |
|
obesity |
20 |
|
adiponectin |
19 |
|
inflammation |
19 |
|
mortality |
18 |
|
pain |
18 |
|
aging |
17 |
|
biology |
17 |
|
cardiovascular disease |
17 |
|
older adults |
17 |
|
adult learning principles |
16 |
|
collaborative practice |
16 |
|
evaluation |
16 |
|
interprofessional education |
16 |
|
rats |
16 |
|
endothelial cells |
15 |
|
nitric oxide |
15 |
|
pharmacy and pharmacology environmental studies |
15 |
|
toxicology and environmental safety |
15 |
|
built environment |
14 |
|
dexmedetomidine |
14 |
|
endothelium |
14 |
|
exercise |
14 |
|
adult |
13 |
|
aged |
13 |
|
anaesthesia |
13 |
|
cirrhosis |
13 |
|
covid-19 |
13 |
|
medical sciences |
13 |
|
mice |
13 |
|
adipose tissue |
12 |
|
cognition |
12 |
|
diabetic cardiomyopathy |
12 |
|
endothelial dysfunction |
12 |
|
endothelial function |
12 |
|
morbidity |
12 |
|
reactive oxygen species |
12 |
|
remifentanil |
12 |
|
animal experiment |
11 |
|
antioxidants |
11 |
|
community health |
11 |
|
dose-response relationship, drug |
11 |
|
hypertension |
11 |
|
local accessibility |
11 |
|
middle aged |
11 |
|
myocardial ischemia injury |
11 |
|
opioid |
11 |
|
ablation |
10 |
|
apoptosis |
10 |
|
atherosclerosis |
10 |
|
bridging therapy |
10 |
|
cardiovascular diseases |
10 |
|
cells, cultured |
10 |
|
contraction |
10 |
|
endothelin-1 |
10 |
|
endothelium-derived contracting factor |
10 |
|
enos |
10 |
|
fgf21 |
10 |
|
hepatocellular carcinoma |
10 |
|
high-intensity focused ultrasound |
10 |
|
liver transplant |
10 |
|
mice, inbred c57bl |
10 |
|
new technology |
10 |
|
sevoflurane |
10 |
|
surgery |
10 |
|
aerosol |
9 |
|
ampk |
9 |
|
blood–brain barrier |
9 |
|
chronic pain |
9 |
|
cyclooxygenase |
9 |
|
disease models, animal |
9 |
|
endothelial nitric oxide synthase |
9 |
|
general anaesthesia |
9 |
|
general anesthesia |
9 |
|
hcc |
9 |
|
hifu |
9 |
|
liver cancer |
9 |
|
mental health |
9 |
|
morphine consumption |
9 |
|
neuroinflammation |
9 |
|
neuropathic pain |
9 |
|
non-invasive treatment |
9 |
|
postoperative |
9 |
|
protein kinase cβ |
9 |
|
rats, sprague-dawley |
9 |
|
signal transduction |
9 |
|
sirt1 |
9 |
|
survival |
9 |
|
vascular smooth muscle |
9 |
|
a-fabp |
8 |
|
adipokine |
8 |
|
age-friendliness |
8 |
|
bradykinin |
8 |
|
cognitive functioning |
8 |
|
depressive symptoms |
8 |
|
endothelium-dependent contractions |
8 |
|
endothelium-derived contracting factors |
8 |
|
functional abilities |
8 |
|
functional ability |
8 |
|
health outcomes |
8 |
|
healthy aging |
8 |
|
heme oxygenase-1 |
8 |
|
hong kong |
8 |
|
ischemic stroke |
8 |
|
jak2/stat3 |
8 |
|
lipocalin-2 |
8 |
|
living environments |
8 |
|
longitudinal study |
8 |
|
neighbourhood physical environments |
8 |
|
nitric oxide - metabolism |
8 |
|
pain management |
8 |
|
patch-clamp techniques |
8 |
|
pi3k/akt |
8 |
|
public open space |
8 |
|
reactive oxygen species - metabolism |
8 |
|
relaxation |
8 |
|
terrain slope |
8 |
|
adipokines |
7 |
|
asia |
7 |
|
blood pressure - drug effects |
7 |
|
cell line |
7 |
|
china |
7 |
|
electrophysiology |
7 |
|
endothelium, vascular - drug effects - metabolism - physiology |
7 |
|
endothelium, vascular - drug effects - metabolism - physiopathology |
7 |
|
enhanced recovery |
7 |
|
health economic analysis |
7 |
|
heart |
7 |
|
hemodynamics - drug effects |
7 |
|
hypothermia |
7 |
|
hypoxia |
7 |
|
imaging |
7 |
|
inflammatory pain |
7 |
|
intranasal |
7 |
|
ischaemic stroke |
7 |
|
jnk/c-jun signalling |
7 |
|
laparoscopic liver resection |
7 |
|
long-term outcome |
7 |
|
macrophages |
7 |
|
mmp-9 |
7 |
|
osteoporosis |
7 |
|
placebo |
7 |
|
postoperative pain |
7 |
|
proliferation |
7 |
|
prostacyclin |
7 |
|
rct |
7 |
|
soluble guanylyl cyclase |
7 |
|
survival analysis |
7 |
|
time factors |
7 |
|
vasoconstriction |
7 |
|
vasoconstriction - drug effects |
7 |
|
adenosine |
6 |
|
anesthetics, inhalation - pharmacology |
6 |
|
anesthetics, intravenous - pharmacology |
6 |
|
antioxidants - therapeutic use |
6 |
|
aorta |
6 |
|
biogenesis |
6 |
|
blood coagulation |
6 |
|
cell density |
6 |
|
coagulation |
6 |
|
complications |
6 |
|
diabetes mellitus |
6 |
|
elisa |
6 |
|
empathy |
6 |
|
endothelial senescence |
6 |
|
endothelium, vascular - physiology |
6 |
|
endothelium-derived hyperpolarizing factor |
6 |
|
enzyme inhibitors - pharmacology |
6 |
|
ep4 |
6 |
|
film |
6 |
|
genistein |
6 |
|
heart rate - drug effects |
6 |
|
hypercholesterolemia |
6 |
|
intraoperative care |
6 |
|
ischemia reperfusion injury |
6 |
|
isoproterenol |
6 |
|
lipocalin |
6 |
|
lkb1 |
6 |
|
medical humanities |
6 |
|
mitochondrial dysfunction |
6 |
|
muscle relaxation - drug effects |
6 |
|
muscle, smooth, vascular - drug effects - metabolism |
6 |
|
myocardial ischaemia/reperfusion |
6 |
|
opioids |
6 |
|
pain - drug therapy |
6 |
|
perioperative |
6 |
|
perioperative management |
6 |
|
prevalence |
6 |
|
rat |
6 |
|
rats, inbred shr |
6 |
|
rats, inbred wky |
6 |
|
reflective thinking |
6 |
|
sirt3 |
6 |
|
social deprivation |
6 |
|
spatial uncertainty |
6 |
|
spinal cord stimulation |
6 |
|
supraglottic airway device |
6 |
|
tp receptors |
6 |
|
vasodilatation |
6 |
|
17β-estradiol |
5 |
|
acetylcholine - pharmacology |
5 |
|
acetylcysteine - pharmacology - therapeutic use |
5 |
|
acute |
5 |
|
acute kidney injury |
5 |
|
acute postoperative pain |
5 |
|
adaptor proteins, signal transducing - antagonists and inhibitors - genetics - physiology |
5 |
|
adaptor proteins, signal transducing - metabolism |
5 |
|
adenine - analogs and derivatives - metabolism - pharmacology |
5 |
|
adipocyte fatty-acid-binding protein |
5 |
|
adiponectin - biosynthesis - metabolism |
5 |
|
adiponectin - deficiency - therapeutic use |
5 |
|
adiponectin - metabolism |
5 |
|
adolescent |
5 |
|
advanced ovarian cancer |
5 |
|
aerosol box |
5 |
|
affinity chromatography |
5 |
|
aganglionic megacolon |
5 |
|
aging - metabolism |
5 |
|
allopurinol - pharmacology - therapeutic use |
5 |
|
amp-activated protein kinases - metabolism |
5 |
|
anaesthesiology |
5 |
|
analgesia, patient-controlled |
5 |
|
antineoplastic activity |
5 |
|
antioxidants - pharmacology - therapeutic use |
5 |
|
aorta, thoracic - drug effects - metabolism - physiopathology |
5 |
|
aspirin |
5 |
|
astrocytes |
5 |
|
autoimmune hypoglycaemia |
5 |
|
bile acids |
5 |
|
bilirubin |
5 |
|
binding, competitive |
5 |
|
bioaccumulation |
5 |
|
biomarker |
5 |
|
biotin |
5 |
|
blood loss |
5 |
|
brachial plexus |
5 |
|
breast cancer |
5 |
|
calcium |
5 |
|
camp |
5 |
|
cancer |
5 |
|
cardiac dysfunction |
5 |
|
cardio-renal metabolic syndrome |
5 |
|
cardiology - education |
5 |
|
cardiovascular diseases - metabolism - physiopathology |
5 |
|
carrier proteins - metabolism |
5 |
|
cell aging - drug effects - physiology |
5 |
|
cell cycle proteins - metabolism |
5 |
|
chemicals and cas registry numbers |
5 |
|
child |
5 |
|
children |
5 |
|
cholesterol homeostasis |
5 |
|
ciclosporin |
5 |
|
cognitive dysfunction |
5 |
|
coronary vessels - anatomy and histology - drug effects - metabolism |
5 |
|
cyp2c9 |
5 |
|
cyp7a1 |
5 |
|
cytochrome 3a4 |
5 |
|
cytoreduction |
5 |
|
dementia |
5 |
|
dental |
5 |
|
descriptive epidemiology |
5 |
|
dexmedetomidine - administration and dosage |
5 |
|
diabetes complications - drug therapy - metabolism - pathology - physiopathology |
5 |
|
diabetes mellitus, type 2 - enzymology |
5 |
|
diagnosis |
5 |
|
double-blind method |
5 |
|
education, medical, undergraduate |
5 |
|
endothelial cells - drug effects - metabolism - physiology |
5 |
|
endothelial nitric oxide synthase/nitric oxide (enos/no) pathway |
5 |
|
endothelial regeneration |
5 |
|
endothelin-1 - metabolism |
5 |
|
endothelium, vascular - drug effects - physiopathology |
5 |
|
endothelium, vascular - metabolism |
5 |
|
endothelium-dependent hyperpolarization |
5 |
|
escherichia coli - genetics |
5 |
|
fatty acid-binding proteins - physiology |
5 |
|
fbxo9 |
5 |
|
gender |
5 |
|
gene knockdown techniques |
5 |
|
genistein - metabolism - pharmacology |
5 |
|
gluconeogenesis |
5 |
|
glucose - biosynthesis - metabolism |
5 |
|
glycogen synthase kinase |
5 |
|
healthy city |
5 |
|
healthy living |
5 |
|
heart failure |
5 |
|
hemostatics - therapeutic use |
5 |
|
hepatocytes - enzymology |
5 |
|
herb-drug interaction |
5 |
|
herbal teas |
5 |
|
hip fractures - surgery |
5 |
|
histamine |
5 |
|
hscr |
5 |
|
humdisease |
5 |
|
hyperalgesia |
5 |
|
hyperglycemia |
5 |
|
hypertriglyceridemia |
5 |
|
infant |
5 |
|
infarct size |
5 |
|
infection |
5 |
|
inflammation - immunology - metabolism |
5 |
|
insulin - metabolism |
5 |
|
insulin receptor autoantibodies |
5 |
|
interaction profiling |
5 |
|
ionization time of flight mass spectrometry |
5 |
|
ischaemic heart disease |
5 |
|
isoflurane |
5 |
|
janus-activated kinase |
5 |
|
jnk mitogen-activated protein kinases - genetics - metabolism |
5 |
|
l-arginine |
5 |
|
left ventricular hypertrophy |
5 |
|
lipocalins - genetics - physiology |
5 |
|
lipoprotein lipase |
5 |
|
liquid chromatography-tan-dem mass spectrometry |
5 |
|
longevity regulator |
5 |
|
macrophages - metabolism |
5 |
|
manikin, intubation tent |
5 |
|
matrix-assisted laser desorption |
5 |
|
medical audit |
5 |
|
mice, obese |
5 |
|
midazolam |
5 |
|
mitochondrial proteins - genetics - metabolism |
5 |
|
monitoring, intraoperative - methods |
5 |
|
morphine - administration & dosage |
5 |
|
mouse model |
5 |
|
multinodular goiter |
5 |
|
muscle contraction - drug effects |
5 |
|
muscle, smooth, vascular - physiology |
5 |
|
myocardial hypertrophy and dysfunction |
5 |
|
na+-k+-atpase |
5 |
|
nerve tissue proteins - metabolism |
5 |
|
nervous system development |
5 |
|
neural crest progenitors |
5 |
|
neurog2 |
5 |
|
nf-κb |
5 |
|
nfκb |
5 |
|
nitric oxide synthase |
5 |
|
norepinephrine - pharmacology |
5 |
|
nrf2 |
5 |
|
obesity - metabolism - physiopathology |
5 |
|
obesity - physiopathology |
5 |
|
oncogene proteins - deficiency - genetics - physiology |
5 |
|
oncology |
5 |
|
oxygen - metabolism |
5 |
|
pain measurement |
5 |
|
pain, postoperative - drug therapy |
5 |
|
polyamination |
5 |
|
porphyrin derivative |
5 |
|
potassium channels |
5 |
|
propofol - pharmacology |
5 |
|
prospective studies |
5 |
|
prostaglandin |
5 |
|
prostaglandin e2 |
5 |
|
prostanoids |
5 |
|
protein binding |
5 |
|
protein interaction mapping - methods |
5 |
|
protein kinase a |
5 |
|
protein kinase inhibitors - metabolism - pharmacology |
5 |
|
proteins - metabolism |
5 |
|
proteomics |
5 |
|
proto-oncogene proteins c-akt - metabolism |
5 |
|
public housing |
5 |
|
rapid sequence intubation |
5 |
|
rat mesenteric arteries |
5 |
|
recombinant proteins - genetics - metabolism |
5 |
|
regional anaesthesia |
5 |
|
riot |
5 |
|
rna interference |
5 |
|
ros |
5 |
|
ruboxistaurin |
5 |
|
sedation |
5 |
|
signal transducer and activator of transcription 3 |
5 |
|
signaling |
5 |
|
sirolimus |
5 |
|
sirtuin 1 |
5 |
|
sirtuin 3 |
5 |
|
sirtuins - genetics - metabolism |
5 |
|
socioeconomic factors |
5 |
|
sox10 |
5 |
|
stem cells - drug effects - metabolism - physiology |
5 |
|
students, medical |
5 |
|
tau |
5 |
|
telomere |
5 |
|
tomography, x-ray computed |
5 |
|
total intravenous anesthesia |
5 |
|
traditional chinese medicine |
5 |
|
transcription factor ap-1 - genetics - metabolism |
5 |
|
transcription factor yy1 |
5 |
|
ttf1 |
5 |
|
type b insulin resistance |
5 |
|
acacetin |
4 |
|
acetylcholine |
4 |
|
action potentials - drug effects |
4 |
|
acupuncture analgesia |
4 |
|
acute pain |
4 |
|
adipocyte fatty acid binding protein |
4 |
|
adipokines - metabolism - pharmacology |
4 |
|
adiponectin - deficiency - hysiology - therapeutic use |
4 |
|
adiponectin receptor |
4 |
|
adipor |
4 |
|
adult population |
4 |
|
adverse effects |
4 |
|
ageing |
4 |
|
alzheimer's disease |
4 |
|
amino acid substitution |
4 |
|
amyloidosis |
4 |
|
analgesics |
4 |
|
analgesics - therapeutic use |
4 |
|
analgesics, opioid - pharmacology |
4 |
|
analgesics, opioid - therapeutic use |
4 |
|
analysis of variance |
4 |
|
anesthesia |
4 |
|
anesthesia, general |
4 |
|
anesthesia, obstetrical |
4 |
|
angiotensin ii |
4 |
|
animal model |
4 |
|
antibody drug candidate |
4 |
|
antioxidants - pharmacology |
4 |
|
aorta - physiology |
4 |
|
apocynin |
4 |
|
apolipoprotein |
4 |
|
astrocyte |
4 |
|
audiovisual aids |
4 |
|
autoimmunity |
4 |
|
biological factors - pharmacology |
4 |
|
biological markers |
4 |
|
bispectral index (bis) |
4 |
|
blood loss, surgical - prevention & control |
4 |
|
blood pressure - drug effects - physiology |
4 |
|
blood pressure - physiology |
4 |
|
blood transfusion |
4 |
|
blood vessels - drug effects - metabolism |
4 |
|
blotting, western |
4 |
|
bms309403 |
4 |
|
brg1 |
4 |
|
c-jun n-terminal kinase |
4 |
|
calcium dysfunction |
4 |
|
cardioprotection |
4 |
|
cardiovascular diseases - metabolism - prevention and control |
4 |
|
carotid artery |
4 |
|
caveolin-3 |
4 |
|
cgmp |
4 |
|
chemokines |
4 |
|
child, preschool |
4 |
|
chronic disease |
4 |
|
clinical competence |
4 |
|
clinical outcomes |
4 |
|
clinical pathway |
4 |
|
colorectal surgery |
4 |
|
comprehension |
4 |
|
conscious sedation - methods |
4 |
|
coronary vessels - drug effects - metabolism - physiology |
4 |
|
coronary vessels - drug effects - physiology |
4 |
|
coronavirus |
4 |
|
cox-1 |
4 |
|
creb-h |
4 |
|
critical pathways - organization and administration |
4 |
|
cyclic gmp - biosynthesis |
4 |
|
cyclic gmp - metabolism |
4 |
|
cyclooxygenase 1 - physiology |
4 |
|
cyclooxygenase 2 - physiology |
4 |
|
deamino arginine vasopressin - pharmacology |
4 |
|
dental surgery |
4 |
|
desmopressin |
4 |
|
diabetes mellitus, experimental - drug therapy - metabolism |
4 |
|
diabetic complication |
4 |
|
distal radial fracture fixation |
4 |
|
dogs |
4 |
|
edcf |
4 |
|
electric stimulation |
4 |
|
electroacupuncture |
4 |
|
endocrinology |
4 |
|
endothelial cells - drug effects - metabolism |
4 |
|
endothelial factors |
4 |
|
endothelium, vascular - physiopathology |
4 |
|
endothelium-dependent relaxing factors - pharmacology |
4 |
|
endothelium-derivedcontractingfactor(s) |
4 |
|
epidermal growth factor receptor transactivation |
4 |
|
et-1 |
4 |
|
extracellular matrix |
4 |
|
fgfr1 |
4 |
|
fish oil |
4 |
|
flavones - metabolism - pharmacology |
4 |
|
fractured neck of femur |
4 |
|
g protein activation |
4 |
|
genomics |
4 |
|
geriatric hip fracture |
4 |
|
gi proteins |
4 |
|
gi/o protein |
4 |
|
glucose transporter type 2 |
4 |
|
glucose-stimulated insulin secretion |
4 |
|
gtp-binding protein alpha subunits, gi-go - metabolism |
4 |
|
guanylate cyclase - antagonists & inhibitors |
4 |
|
guidelines |
4 |
|
guinea pigs |
4 |
|
hek293 cells |
4 |
|
hemin |
4 |
|
hemostasis - drug effects |
4 |
|
hepatectomy |
4 |
|
high intensity focused ultrasound |
4 |
|
high-fat diet |
4 |
|
high-fat-diet-induced obesity |
4 |
|
hkv1.5 |
4 |
|
hot temperature |
4 |
|
human |
4 |
|
human neural stem cells |
4 |
|
hypertension - physiopathology |
4 |
|
hypnotics and sedatives |
4 |
|
immune response |
4 |
|
infraclavicular nerve block |
4 |
|
infusions, parenteral |
4 |
|
innate immunity |
4 |
|
intermittent hypoxia |
4 |
|
interventional radiology |
4 |
|
intrathecal morphine |
4 |
|
intravenous: propofol |
4 |
|
ion channel gating - drug effects |
4 |
|
ischaemia/reperfusion injury |
4 |
|
ischemic preconditioning |
4 |
|
isoflurane - pharmacology |
4 |
|
isoflurane postconditioning |
4 |
|
klb |
4 |
|
kv1.5 potassium channel - antagonists and inhibitors - chemistry - genetics |
4 |
|
laparoscopy |
4 |
|
large-conductance calcium-activated potassium channels - antagonists & inhibitors |
4 |
|
length of stay - statistics and numerical data |
4 |
|
lipids |
4 |
|
liver tumor |
4 |
|
local |
4 |
|
membrane estrogen receptor |
4 |
|
metabolic regulation |
4 |
|
methods |
4 |
|
microarray |
4 |
|
molar, third - surgery |
4 |
|
morphine |
4 |
|
motor neurons |
4 |
|
mouse models |
4 |
|
multidisciplinary |
4 |
|
multiple lowdose streptozotocin-induced diabetes |
4 |
|
muscle, smooth, vascular - drug effects - metabolism - physiology |
4 |
|
myocardial ischaemia/reperfusion injury |
4 |
|
myocardial reperfusion injury |
4 |
|
myocardium - pathology |
4 |
|
narcotic antagonists - pharmacology |
4 |
|
natriuretic peptides - pharmacology - physiology |
4 |
|
nephrology |
4 |
|
neutralizing monoclonal antibody 6h2 |
4 |
|
nf-kappa b - metabolism |
4 |
|
nitric oxide - metabolism - pharmacology - physiology |
4 |
|
nitric oxide donors - pharmacology |
4 |
|
nitric oxide synthase type iii - metabolism |
4 |
|
no |
4 |
|
open channel blockade |
4 |
|
osmolar concentration |
4 |
|
oxadiazoles - pharmacology |
4 |
|
oxazines - pharmacology |
4 |
|
oxidation-reduction |
4 |
|
oxygen-derived free radicals |
4 |
|
paediatric |
4 |
|
pain, postoperative - diagnosis - prevention and control |
4 |
|
patient care team - organization and administration |
4 |
|
patient simulation |
4 |
|
peptides - pharmacology |
4 |
|
pertussis toxin |
4 |
|
pethidine |
4 |
|
pharmacology |
4 |
|
phosphorylation |
4 |
|
pig coronary artery |
4 |
|
pilot projects |
4 |
|
pkc-ε |
4 |
|
pluripotent stem cells |
4 |
|
pneumonia |
4 |
|
polyunsaturated fatty acids |
4 |
|
porcine coronary artery angioplasty |
4 |
|
postoperative analgesia |
4 |
|
postoperative opioid consumption |
4 |
|
potassium channel blockers - metabolism - pharmacology |
4 |
|
ppar gamma - agonists - metabolism |
4 |
|
pparγ |
4 |
|
pregnancy |
4 |
|
preoperative assessment |
4 |
|
prostacyclin synthase |
4 |
|
quality of life |
4 |
|
rabbits |
4 |
|
rap1 |
4 |
|
rate-dependent blockade |
4 |
|
receptors, adiponectin - metabolism |
4 |
|
regeneration |
4 |
|
regional anesthesia |
4 |
|
repeated non-invasive limb ischemic preconditioning |
4 |
|
reproducibility of results |
4 |
|
respiratory infectious disease |
4 |
|
retrospective studies |
4 |
|
risk factors |
4 |
|
scoliosis - surgery |
4 |
|
serotonin |
4 |
|
shock - metabolism - physiopathology |
4 |
|
signal transduction - drug effects |
4 |
|
smooth muscle cell |
4 |
|
sox9 |
4 |
|
spatial heterogeneity |
4 |
|
spinal cord |
4 |
|
spinal cord injury |
4 |
|
spontaneously hypertensive rats |
4 |
|
stat3 |
4 |
|
statins |
4 |
|
stress |
4 |
|
superoxide dismutase - metabolism |
4 |
|
surgical procedures, operative |
4 |
|
surgical wound infection - prevention and control |
4 |
|
surveys and questionnaires |
4 |
|
swine |
4 |
|
teaching - methods |
4 |
|
thermal ablation |
4 |
|
thiazolidinediones - therapeutic use |
4 |
|
tonic blockade |
4 |
|
tooth extraction - adverse effects |
4 |
|
total intravenous anaesthesia (tiva) |
4 |
|
tp receptor |
4 |
|
transfection |
4 |
|
type 1diabetes |
4 |
|
urban environment |
4 |
|
vascular |
4 |
|
vascular diseases - physiopathology - prevention & control |
4 |
|
vascular homeostasis |
4 |
|
vasculature |
4 |
|
vasoconstriction/dilation |
4 |
|
vasodilation |
4 |
|
vasodilation - drug effects - physiology |
4 |
|
young adult |
4 |
|
1-(5-isoquinolinesulfonyl)-2-methylpiperazine - analogs & derivatives - chemistry - pharmacology |
3 |
|
3′-5′-cyclic adenosine monophosphate (cyclic amp) |
3 |
|
8-bromo cyclic adenosine monophosphate - pharmacology |
3 |
|
acetylation |
3 |
|
acupuncture |
3 |
|
acute disease |
3 |
|
acute myocardial infarction |
3 |
|
adenylate cyclase - metabolism |
3 |
|
administration, oral |
3 |
|
adrenergic alpha-2 receptor agonists - pharmacology |
3 |
|
adrenergic beta-antagonists - pharmacology |
3 |
|
age distribution |
3 |
|
aged, 80 and over |
3 |
|
algorithms |
3 |
|
allopurinol |
3 |
|
amides - chemistry - pharmacology |
3 |
|
amp-activated protein kinase |
3 |
|
amygdala |
3 |
|
anaesthetics i.v., propofol |
3 |
|
anaesthetics volatile, sevoflurane |
3 |
|
analgesia - adverse effects |
3 |
|
analgesia intra-articular |
3 |
|
analgesic efficacy |
3 |
|
analgesics non-opioid ketorolac |
3 |
|
analgesics, opioid |
3 |
|
analgesics, opioid - administration & dosage |
3 |
|
analgesics, opioid - administration and dosage |
3 |
|
analgesics, opioid - adverse effects |
3 |
|
analgesics, opioid - metabolism - therapeutic use |
3 |
|
anesthesia recovery period |
3 |
|
anesthesia, local |
3 |
|
anesthesia, spinal |
3 |
|
anesthetics |
3 |
|
aneurysms |
3 |
|
ang ii type 1 receptors |
3 |
|
anoxia - metabolism - physiopathology |
3 |
|
anti-arrhythmia agents - pharmacology |
3 |
|
anti-inflammation |
3 |
|
anti-inflammatory agents - pharmacology - therapeutic use |
3 |
|
anti-inflammatory agents, non-steroidal - therapeutic use |
3 |
|
antifibrinolytic agents - therapeutic use |
3 |
|
antihypertensive agents - chemistry - pharmacology |
3 |
|
aorta - drug effects |
3 |
|
aorta - metabolism |
3 |
|
aorta, thoracic - drug effects - enzymology - physiopathology |
3 |
|
apoptosis - drug effects |
3 |
|
arginine - pharmacology |
3 |
|
arrhythmia |
3 |
|
arteries - metabolism - physiology |
3 |
|
arthroplasty, replacement, knee |
3 |
|
atherosclerosis - enzymology - pathology |
3 |
|
atrial fibrillation - drug therapy - prevention & control |
3 |
|
atrial function - drug effects |
3 |
|
atropine - pharmacology |
3 |
|
auditing |
3 |
|
autophagy |
3 |
|
basement membrane |
3 |
|
berberine - pharmacology - therapeutic use |
3 |
|
biological effects |
3 |
|
blended learning |
3 |
|
blood vessel remodeling |
3 |
|
bone marrow |
3 |
|
bone morphogenetic protein 4 - antagonists & inhibitors - metabolism |
3 |
|
bone morphogenetic protein receptors, type i - metabolism |
3 |
|
bone morphogenic protein 4 |
3 |
|
bupivacaine |
3 |
|
burden of disease |
3 |
|
calcimycin - pharmacology |
3 |
|
calcium - metabolism |
3 |
|
calcium channel blockers - pharmacology |
3 |
|
calcium channels - metabolism |
3 |
|
calcium sensitization |
3 |
|
camp-dependent protein kinase |
3 |
|
cancer chemotherapy |
3 |
|
cardiac biomarkers |
3 |
|
cardiac complications |
3 |
|
cardiac output |
3 |
|
cardiac protection |
3 |
|
cardiotonic agents |
3 |
|
cardiotonic agents - pharmacology |
3 |
|
cardiovascular agents - administration & dosage |
3 |
|
cardiovascular diseases - drug therapy - physiopathology |
3 |
|
carrier proteins - metabolism - pharmacology |
3 |
|
catalase - drug effects - metabolism |
3 |
|
caveolae |
3 |
|
cell adhesion |
3 |
|
cell aging - physiology |
3 |
|
cell isolation |
3 |
|
cell proliferation - drug effects |
3 |
|
cell survival - drug effects |
3 |
|
cesarean section |
3 |
|
cgmp-dependent protein kinase |
3 |
|
cgmp-dependent protein kinase, porcine coronary artery |
3 |
|
chemobrain |
3 |
|
chloral hydrate |
3 |
|
chromatography, high pressure liquid |
3 |
|
chronic |
3 |
|
chronic post-ischaemic pain |
3 |
|
chronic post-ischemia pain |
3 |
|
chronic regional pain syndrome |
3 |
|
circulating tumour cells |
3 |
|
clinical effectiveness |
3 |
|
clonidine |
3 |
|
cognition dysfunction |
3 |
|
colorectal |
3 |
|
comorbidity |
3 |
|
continuous femoral nerve block |
3 |
|
contrast media |
3 |
|
controlled study |
3 |
|
coronary artery bypass graft surgery |
3 |
|
coronary artery, porcine |
3 |
|
coronary vessels - drug effects - enzymology - physiology |
3 |
|
coronary vessels - drug effects - metabolism - physiopathology |
3 |
|
coronary vessels - physiology |
3 |
|
cross-over studies |
3 |
|
crossover procedure |
3 |
|
curriculum |
3 |
|
cxcl12 |
3 |
|
cxcl12/cxcr4 axis |
3 |
|
cxcr4 |
3 |
|
cyclic amp - physiology |
3 |
|
cyclic amp-dependent protein kinases - physiology |
3 |
|
cyclic gmp-dependent protein kinases - chemistry - physiology |
3 |
|
cyclic gmp-dependent protein kinases - metabolism |
3 |
|
cyclic guanosine monophosphate |
3 |
|
cyclic nucleotides |
3 |
|
cyclin-dependent kinase 5 |
3 |
|
cyclin-dependent kinase 5 - antagonists and inhibitors - physiology |
3 |
|
cyclooxygenase 2 - genetics - metabolism |
3 |
|
cyclooxygenase 2 - metabolism |
3 |
|
cyclooxygenase inhibitors - administration & dosage - blood - therapeutic use |
3 |
|
cyclooxygenase-2 |
3 |
|
cyclooxygenases |
3 |
|
cytokines |
3 |
|
cytokines and epigenetics |
3 |
|
damage |
3 |
|
data collection |
3 |
|
deamino arginine vasopressin - therapeutic use |
3 |
|
delirium |
3 |
|
depression |
3 |
|
dexmedetomidine - administration and dosage - adverse effects - pharmacology |
3 |
|
dexmedetomidine - pharmacology |
3 |
|
diabetes mellitus, experimental - chemically induced - metabolism - physiopathology |
3 |
|
difficult airway |
3 |
|
dihydropyridine |
3 |
|
dihydropyridines - pharmacology |
3 |
|
disulfide bonds |
3 |
|
double blind procedure |
3 |
|
drug administration schedule |
3 |
|
drugs |
3 |
|
e-learning |
3 |
|
eicosanoids |
3 |
|
endothelial cells - drug effects - enzymology |
3 |
|
endothelial cells - drug effects - physiology |
3 |
|
endothelial cells - metabolism |
3 |
|
endothelin type a receptor |
3 |
|
endothelin-1 - genetics - metabolism |
3 |
|
endothelium, vascular - drug effects - enzymology - physiology |
3 |
|
endothelium, vascular - drug effects - metabolism |
3 |
|
endothelium, vascular - enzymology |
3 |
|
endothelium, vascular - enzymology - metabolism - pathology |
3 |
|
endothelium-dependent contraction |
3 |
|
endothelium-derived hyperpolarization |
3 |
|
endotoxemia |
3 |
|
endovascular procedures |
3 |
|
enhanced recovery after surgery |
3 |
|
environmental inequality |
3 |
|
enzyme activation |
3 |
|
enzyme activation - drug effects |
3 |
|
ep4 receptor |
3 |
|
equilibrative nucleoside transporter 1 - antagonists & inhibitors - genetics - metabolism |
3 |
|
equilibrative-nucleoside transporter 2 - antagonists & inhibitors - genetics - metabolism |
3 |
|
erythropoiesis |
3 |
|
erythropoietin |
3 |
|
estradiol - pharmacology |
3 |
|
estrogen |
3 |
|
estrogen receptor beta |
3 |
|
evoked potentials, somatosensory - drug effects |
3 |
|
experimental mouse model |
3 |
|
extremely hot weather event |
3 |
|
fascia iliaca block |
3 |
|
fat |
3 |
|
femoral artery - drug effects - metabolism - physiopathology |
3 |
|
femoral neck fracture |
3 |
|
femoral nerve |
3 |
|
fentanyl |
3 |
|
flavones - pharmacology - therapeutic use |
3 |
|
forkhead box protein o1 |
3 |
|
formaldehyde |
3 |
|
fractured hip |
3 |
|
frailty |
3 |
|
free radical scavengers |
3 |
|
g-proteins |
3 |
|
gap junction |
3 |
|
geriatric fracture hip |
3 |
|
geriatric trauma |
3 |
|
gerotarget |
3 |
|
glial–glial crosstalk |
3 |
|
global |
3 |
|
glucocorticoid receptor |
3 |
|
greenspace exposure |
3 |
|
guanylate cyclase - chemistry - physiology |
3 |
|
gut microbiota |
3 |
|
haemoglobin |
3 |
|
health surveys |
3 |
|
healthcare utilisation |
3 |
|
heart infarction size |
3 |
|
heart muscle ischemia |
3 |
|
heart-type fatty acid binding protein |
3 |
|
hemodilution |
3 |
|
hemodynamics |
3 |
|
hepatic ischaemiareperfusion injury |
3 |
|
hip fracture repair |
3 |
|
hydrogen peroxide |
3 |
|
hydrogen peroxide - antagonists & inhibitors - pharmacology |
3 |
|
hydrogen peroxide - metabolism |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use |
3 |
|
hyperglycemia - drug therapy - metabolism |
3 |
|
hyperlipidemia |
3 |
|
hypertension - drug therapy - enzymology - physiopathology |
3 |
|
hypertension - drug therapy - physiopathology |
3 |
|
hypertension - genetics - metabolism |
3 |
|
hypertension, renal - metabolism |
3 |
|
hypotension |
3 |
|
hypotension - chemically induced |
3 |
|
hypotension - etiology |
3 |
|
hypothermia - blood |
3 |
|
ibuprofen |
3 |
|
il-6 |
3 |
|
in ovo electroporation |
3 |
|
inflammation - drug therapy - physiopathology |
3 |
|
infusions, intravenous |
3 |
|
injections, spinal |
3 |
|
inos |
3 |
|
insomnia |
3 |
|
intermediate-conductance calcium-activated potassium channels |
3 |
|
intubation, intratracheal |
3 |
|
ion channels |
3 |
|
ischaemia reperfusion injury |
3 |
|
ischemia |
3 |
|
ischemic postconditioning - methods |
3 |
|
ischemic preconditioning, myocardial |
3 |
|
ischemic preconditioning, myocardial - methods |
3 |
|
isoflurane - therapeutic use |
3 |
|
isometric contraction - drug effects |
3 |
|
isoproterenol - pharmacology |
3 |
|
isoxazoles - administration & dosage - blood - therapeutic use |
3 |
|
issue 148 |
3 |
|
jnk |
3 |
|
kaempferol |
3 |
|
kaempferols - pharmacology |
3 |
|
ketorolac - administration & dosage - blood - therapeutic use |
3 |
|
large-conductance calcium-activated potassium channels - agonists |
3 |
|
laryngeal mask airway |
3 |
|
liver |
3 |
|
liver - blood supply - drug effects - metabolism |
3 |
|
liver diseases - metabolism - prevention and control |
3 |
|
liver transplantation |
3 |
|
lung cancer incidence |
3 |
|
machine learning |
3 |
|
map kinase signaling system - physiology |
3 |
|
matrix metalloproteinase-2 |
3 |
|
maxilla - surgery |
3 |
|
medicine, chinese traditional |
3 |
|
melanoma |
3 |
|
mental distress |
3 |
|
meperidine |
3 |
|
mesenteric arteries - drug effects |
3 |
|
mesenteric artery, superior - drug effects - enzymology |
3 |
|
meta-analysis |
3 |
|
metabolic syndrome |
3 |
|
metastasis prediction |
3 |
|
metastatic |
3 |
|
methodology |
3 |
|
microcirculation |
3 |
|
microscopy, confocal - methods |
3 |
|
minimally invasive surgery |
3 |
|
mitochondria |
3 |
|
models, biological |
3 |
|
modernization |
3 |
|
modification effects |
3 |
|
monitoring |
3 |
|
monitoring, somatosensory evoked potential |
3 |
|
morphine - administration and dosage |
3 |
|
morphine - administration and dosage - metabolism |
3 |
|
morphine - adverse effects |
3 |
|
morphine - pharmacology |
3 |
|
multi-component care bundle |
3 |
|
muscle contraction - drug effects - physiology |
3 |
|
myocardial contraction - drug effects |
3 |
|
myocardial infarction |
3 |
|
myocardial infarction - metabolism - pathology - prevention & control |
3 |
|
myocardial injury |
3 |
|
myocardial ischemia |
3 |
|
myocardial ischemia-reperfusion |
3 |
|
myocardial reperfusion injury - metabolism - pathology - prevention & control |
3 |
|
myocardial reperfusion injury - prevention and control |
3 |
|
myocytes, cardiac |
3 |
|
n-methyl-d-aspartate receptors |
3 |
|
nausea - chemically induced |
3 |
|
nedd9 |
3 |
|
nerve block - adverse effects |
3 |
|
nerve block - methods |
3 |
|
neuromodulator |
3 |
|
neuropathic |
3 |
|
nitrative stress |
3 |
|
nitric oxide synthase - drug effects - metabolism |
3 |
|
nitrosative stress |
3 |
|
nociceptors - drug effects |
3 |
|
non-cancer pain |
3 |
|
non-genomic effects |
3 |
|
noncardiac surgery |
3 |
|
nongenomic |
3 |
|
notoginsenoside ft1 |
3 |
|
nuclear factor of activated t-cells 5 |
3 |
|
nuclear factor-kappa b |
3 |
|
nucleoside |
3 |
|
ondansetron - therapeutic use |
3 |
|
operative |
3 |
|
opioid requirements |
3 |
|
opioid rotation |
3 |
|
opioid therapy |
3 |
|
organ culture techniques |
3 |
|
osteotomy - adverse effects - methods |
3 |
|
outcome |
3 |
|
oxidants - pharmacology |
3 |
|
oxidative stress - drug effects |
3 |
|
oxidative stress - physiology |
3 |
|
oxygen - blood |
3 |
|
oxygen consumption - physiology |
3 |
|
p21 |
3 |
|
p25 |
3 |
|
p38 mitogen-activated protein kinases - metabolism |
3 |
|
pain clinics - standards |
3 |
|
pain measurement - methods |
3 |
|
pain, postoperative - prevention and control |
3 |
|
pain: postoperative |
3 |
|
painpaired box gene 2 |
3 |
|
panax notoginseng |
3 |
|
parecoxib |
3 |
|
pathological pain |
3 |
|
pathophysiological changes |
3 |
|
patient-controlled |
3 |
|
perceived pain intensity |
3 |
|
perioperative care |
3 |
|
peroxisome proliferator-activated receptor agonist |
3 |
|
persistent opioid use |
3 |
|
personal wellbeing |
3 |
|
pharmacogenetics |
3 |
|
pi3k |
3 |
|
piperidines - therapeutic use |
3 |
|
pkg |
3 |
|
pm1 |
3 |
|
pneumothorax |
3 |
|
polymorphisms |
3 |
|
populations/contexts |
3 |
|
post-ischemic myocardial injury |
3 |
|
postconditioning |
3 |
|
postoperative care |
3 |
|
postoperative cognitive dysfunction |
3 |
|
postoperative complications |
3 |
|
postoperative complications - prevention & control |
3 |
|
postoperative nausea and vomiting |
3 |